Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by NorthStar Medical Radioisotopes, LLC

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Unveils Radiopharmaceutical Contract Development & Manufacturing (CDMO) Facility
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes to Participate in October 2024 Oppenheimer Conference
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes and Convergent Therapeutics, Inc. Expand Strategic Collaboration Around CONV01-α
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Sponsors Study Entitled “Program to Find a Cure for ANCA-associated Vasculitis Through Research”
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Marks Critical Milestone in Readiness for Clinical Batch Production
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Truist Securities Biopharma Symposium
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals' Therapy Clinical Programs
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Guggenheim Radiopharmaceuticals Day
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Announces Presentations at Upcoming Jefferies Radiopharma Innovation Summit
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Receives Electron Beam Accelerator for First-of-its-Kind, Commercial-scale U.S. Production of Important Therapeutic Radioisotope Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
Radiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
Tickers ASX:RAD
Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron® Electron Beam Accelerators for Commercial Production of Radioisotopes
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
From NorthStar Medical Radioisotopes, LLC
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.